The WTA issues a statement in support of Swiatek and its commitment to clean sport
The International Tennis Integrity Agency (ITIA) has revealed Iga Swiatek's positive test for Trimetazidine, resulting in a one-month suspension for the player between September 22 and October 4, 2024.
The Women's Tennis Association (WTA) reacted with a statement, shared on its social networks:
"The WTA notes the decision of the International Tennis Integrity Association (ITIA) - which administers the Tennis Anti-Doping Program (TADP) - to impose a one-month suspension on Iga Swiatek, following the identification of a contaminated controlled drug (melatonin) as the source of her positive test for the banned substance Trimetazidine.
The WTA fully supports Iga in this difficult period. Iga has always shown a strong commitment to fair play and respect for the principles of clean sport.
This unfortunate incident highlights the challenges athletes face when using drugs and supplements.
The WTA remains firmly committed to clean sport and the rigorous processes that protect the integrity of competition.
We also insist that athletes take every precaution to verify the safety and compliance of all products they use, as even unintentional exposure to banned substances can have significant consequences.
We will continue to work closely with our athletes to provide them with information and resources that enable them to make informed decisions and maintain the highest standards of integrity in our sport."
